High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.180
-0%
--
--
-0.193
+7.41%
--
--
-0.207
+14.82%
Estimates Revision
The market is revising No Change the revenue expectations for DiaMedica Therapeutics Inc. (DMAC) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 40.55%.
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+40.55%
In Past 3 Month
5 Analyst Rating
Wall Street analysts forecast DMAC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DMAC is 17.00 USD with a low forecast of 12.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.630
Low
12.00
Averages
17.00
High
25.00
Current: 8.630
Low
12.00
Averages
17.00
High
25.00
Cantor Fitzgerald
Josh Schimmer
Overweight
initiated
$25
2025-11-14
Reason
Cantor Fitzgerald
Josh Schimmer
Price Target
$25
2025-11-14
initiated
Overweight
Reason
Cantor Fitzgerald analyst Josh Schimmer initiated coverage of DiaMedica Therapeutics with an Overweight rating and $25 price target. DiaMedica has begun to generate very compelling data for DM199 for treatment of pre-eclampsia, with key opinion leaders indicating a very high unmet need and a very high degree of enthusiasm for this product, the analyst tells investors in a research note. The firm estimates peak sales reaching more than $1B by 2033, but believes this will prove quite conservative.
Cantor Fitzgerald
Josh Schimmer
Overweight
initiated
$25
2025-11-14
Reason
Cantor Fitzgerald
Josh Schimmer
Price Target
$25
2025-11-14
initiated
Overweight
Reason
Cantor Fitzgerald analyst Josh Schimmer initiated coverage of DiaMedica Therapeutics with an Overweight rating and $25 price target.
TD Cowen
initiated
2025-10-30
Reason
TD Cowen
Price Target
2025-10-30
initiated
Reason
TD Cowen initiated coverage of DiaMedica Therapeutics with a Buy rating and no price target. The firm says the interim proof of concept data indicates DM199 does not cross the placenta and is a potent vasodilator in preeclampsia, with early signs of enhanced placental perfusion. Key opinion leaders are "enthusiastic" for the potential to treat both hypertension and endothelial dysfunction to drastically improve maternal-fetal outcomes, the analyst tells investors in a research note. TD sees potential $1B in peak sales in early onset preeclampsia alone.
H.C. Wainwright
NULL -> Buy
upgrade
$10 -> $12
2025-07-18
Reason
H.C. Wainwright
Price Target
$10 -> $12
2025-07-18
upgrade
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on DiaMedica Therapeutics to $12 from $10 and keeps a Buy rating on the shares. The firm says that with the positive interim results from Part 1a of the Phase 2 study, there is "tangible evidence" for the therapeutic potential of DM199 across achieved pre-specified efficacy and safety endpoints from the dose escalation.
Lake Street
Buy
maintain
$11 -> $14
2025-07-18
Reason
Lake Street
Price Target
$11 -> $14
2025-07-18
maintain
Buy
Reason
Lake Street raised the firm's price target on DiaMedica Therapeutics to $14 from $11 and keeps a Buy rating on the shares after the company announced interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia that the firm sees "materially" improving the prospects for DM199 in this indication.
Craig-Hallum
Chase Knickerbocker
Buy
maintain
$8 -> $11
2025-07-18
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$8 -> $11
2025-07-18
maintain
Buy
Reason
Craig-Hallum analyst Chase Knickerbocker raised the firm's price target on DiaMedica Therapeutics to $11 from $8 and keeps a Buy rating on the shares following interim results from Part 1a of its Phase 2 trial evaluating DM199 for preeclampsia. The data showed clinically meaningful reductions in both systolic and diastolic blood pressure, with the highest dose group experiencing acute drops of 35 mmHg and 15 mmHg respectively at 5 minutes. While the sample size remains small, the 24-hour average reductions of 20 mmHg systolic and 10 mmHg diastolic are encouraging and the firm says potentially clinically meaningful. These results support continued development into Part 1b and beyond, Craig-Hallum adds. Importantly, evidence suggests DM199 did not cross the placental barrier.
See All Ratings
Valuation Metrics
The current forward P/E ratio for DiaMedica Therapeutics Inc (DMAC.O) is -10.83, compared to its 5-year average forward P/E of -5.23. For a more detailed relative valuation and DCF analysis to assess DiaMedica Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.23
Current PE
-10.83
Overvalued PE
-2.54
Undervalued PE
-7.91
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.01
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.23
Undervalued EV/EBITDA
-5.78
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
DMAC News & Events
Events Timeline
(ET)
2025-11-12
16:34:27
DiaMedica Therapeutics Announces Q3 Earnings Per Share of 17 Cents, Exceeding Consensus Estimate of 16 Cents
2025-08-12 (ET)
2025-08-12
16:19:42
DiaMedica Therapeutics reports Q2 EPS (18c), consensus (19c)
2025-08-06 (ET)
2025-08-06
09:34:09
DiaMedica Therapeutics CMO Lorianne Masuoka resigns, Julie Krop succeeds
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/newsfilter.png)
Preview
1.0
11-10NewsfilterDiaMedica Therapeutics to Attend Jefferies Global Healthcare Conference in London
Preview
5.0
09-30NewsfilterDiaMedica Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(C)(4)
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/ffd55837ac77c9c327dece558caa1c8572d02ff8e8ab7221cfaedecd8323c228.jpg)
Preview
3.0
09-17NASDAQ.COMDiaMedica Therapeutics, Inc. (DMAC) Shows Strong Momentum: Is It a Good Investment?
Sign Up For More News
People Also Watch
FAQ
What is DiaMedica Therapeutics Inc (DMAC) stock price today?
What is DiaMedica Therapeutics Inc (DMAC)'s business?
What is the price predicton of DMAC Stock?
What is DiaMedica Therapeutics Inc (DMAC)'s revenue for the last quarter?
What is DiaMedica Therapeutics Inc (DMAC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for DiaMedica Therapeutics Inc (DMAC)'s fundamentals?
How many employees does DiaMedica Therapeutics Inc (DMAC). have?